Investing.com — Shares of ARS Pharmaceuticals saw a significant rise, hitting a high of 11%, marking the biggest intraday jump since August.
This increase was triggered by the company's announcement of its preliminary fourth-quarter net income for its anti-allergy spray, Neffy, which surpassed analyst predictions.
Neffy's preliminary net product revenue in the fourth quarter was approximately $6.5 million. This figure significantly exceeded the average estimate of $3.11 million projected by analysts, according to a Bloomberg survey.
In 2024, total net product sales amounted to around $7.1 million. This revenue was generated after the anti-allergy spray became available to wholesalers and pharmacies on September 23.
Looking ahead to 2025, ARS Pharmaceuticals has indicated its intention to drive demand and gain more traction among its target prescribers.
This article was generated with the support of ai and reviewed by an editor. For more information consult our T&C.
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=();t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e)(0);s.parentNode.insertBefore(t,s)}(window, document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
